AbD Serotec Introduces Bovine and Ovine Dendritic Cell Growth Kits and Antibodies.
Optimized, species-specific reagents for improved dendritic cell research
Oxford, UK, 10 July 2012: AbD Serotec, a leader in antibody products for veterinary research, has today announced that it has launched bovine and ovine Dendritic Cell Growth Kits and a complementary panel of antibodies for dendritic cell phenotyping. The Dendritic Cell Growth Kits have been developed to improve dendritic cell (DC) generation, by enabling researchers to develop a method for consistent cell generation, and to save time with pre-validated, optimized species-specific reagents. The complementary panel of antibodies for bovine and ovine DC markers has been launched to enable cell surface phenotyping of DCs
The Dendritic Cell Growth Kits are unique to AbD Serotec, and were developed in collaboration with the Moredun Research Institute, Edinburgh and Institute of Animal Health, Compton; centers recognized worldwide for their research in the infectious diseases of livestock. The kits contain biologically active cytokines in liquid format, premixed at optimal concentrations to facilitate the generation of DCs from peripheral blood mononuclear cells.
Amanda Turner, Market Segment Manager, commented, “The Dendritic Cell Growth Kits will enable researchers to establish a method for consistent DC generation, and using optimized and validated reagents will save time. Selecting the most appropriate phenotyping antibodies can be a challenge, so we have therefore highlighted a selection of relevant references on our website, and have an expert technical support team available for advice as needed.”
For detailed information about the Bovine and Ovine Dendritic Cell Growth Kits and Antibodies visit http://bit.ly/LKFRYq
About AbD Serotec
AbD Serotec is a Division of MorphoSys, an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. AbD Serotec is committed to developing veterinary research-specific reagents via collaboration with renowned research organizations, and through the generation of superior monoclonal antibodies using HuCAL® and other technologies. The MorphoSys HuCAL® technology is one of the most powerful methods available for generating fully human antibodies. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol "MOR". HuCAL® is a registered trademark of MorphoSys AG.
Further information on MorphoSys: http://www.morphosys.com/
Amanda Turner, Market Segment Manager
AbD Serotec, MorphoSys UK Ltd
Tel: +44 (0)1865 852700
Tel: +44 (0)7787 502 947